Search results for "Atypical"

showing 10 items of 111 documents

Clinical relevance of myocardial bridging detected by coronary CT angiography in patients with atypical chest pain

2019

MaleChest Painmedicine.medical_specialtycoronary CT angiography atypical chest painMyocardial bridgingComputed Tomography AngiographyMyocardial BridgingCoronary Angiographycoronary CT angiographyHumansMedicineClinical significanceIn patientCoronary VesselAgedbusiness.industryAngiographyAtypical chest painCoronary ct angiographyatypical chest painMiddle AgedCoronary VesselsFemaleRadiologyTomography X-Ray ComputedCardiology and Cardiovascular MedicinebusinessHumanMinerva Cardioangiologica
researchProduct

The use of ziprasidone in clinical practice: Analysis of pharmacokinetic and pharmacodynamic aspects from data of a drug monitoring survey

2008

AbstractThis study related clinical effects to daily doses and serum concentrations of ziprasidone by retrospective analysis of data from a therapeutic drug monitoring (TDM) survey established for patients treated with the new antipsychotic drug. In the total sample of 463 patients ziprasidone doses ranged between 20 and 320 mg/d and correlated significantly (r2 = 0.093, P < 0.01) with serum concentrations. The latter were highly variable within and between individual patients (between patients median 67 ng/ml, 25–75th percentile 40–103 ng/ml). Pharmacokinetic interactions with comedication played a minor role. According to the clinical global impressions (CGI) scale most of the 348 pati…

MaleDrugmedicine.drug_classmedia_common.quotation_subjectAtypical antipsychotic030204 cardiovascular system & hematologyPharmacologySeverity of Illness Index030226 pharmacology & pharmacyDrug Administration SchedulePiperazines03 medical and health sciences0302 clinical medicinePharmacotherapyPharmacokineticsHumansMedicineZiprasidoneRetrospective Studiesmedia_commonDose-Response Relationship Drugmedicine.diagnostic_testMood Disordersbusiness.industryDrug interactionThiazolesPsychiatry and Mental healthTreatment OutcomePsychotic DisordersTherapeutic drug monitoringAnesthesiaPharmacodynamicsDrug Therapy CombinationFemaleDrug MonitoringbusinessAntipsychotic Agentsmedicine.drugEuropean Psychiatry
researchProduct

Pharmacodynamic effects of aripiprazole and ziprasidone with respect to p-glycoprotein substrate properties.

2013

Introduction Aripiprazole, an atypical antipsychotic drug with mixed antagonism and agonism on dopamine D2 and serotonin receptors, is a substrate of the efflux transporter P-glycoprotein (P-gp). Here we tested the pharmacodynamic consequences of these properties in a P-gp deficient mouse model by studying the effects of aripiprazole and of ziprasidone on motor coordination. Methods The motor behaviour of wild-type (WT) and P-gp deficient [abcb1ab(-/-)] mice was investigated on a RotaRod. Mice received acute injections of either aripirazole or ziprasidone. For comparison, the dopamine receptor antagonist haloperidol and serotonin receptor ligands buspirone and ketanserin were also applied. …

MaleKetanserinmedicine.drug_classAripiprazoleAtypical antipsychoticPharmacologyMotor ActivityQuinolonesRotarod performance testPiperazinesBuspironeMiceDopamine receptor D2medicineAnimalsPharmacology (medical)ZiprasidoneATP Binding Cassette Transporter Subfamily B Member 1Mice KnockoutChemistryGeneral MedicineBuspironeSerotonin Receptor AgonistsPsychiatry and Mental healthThiazolesDopamine receptorRotarod Performance TestHaloperidolAripiprazoleKetanserinSerotonin Antagonistsmedicine.drugAntipsychotic AgentsPharmacopsychiatry
researchProduct

Clozapine: Strong antiaggressive effects with minimal motor impairment

1992

Abstract Clinical studies have shown clozapine to be effective in the treatment of schizophrenia and associated with an extremely low incidence of extrapiramidal side effects. Diverse studies indicate that clozapine is an atypical neuroleptic with a preferential activity on the mesolimbic structures and a lower affinity for striatal D2 receptors than the classical antipsychotics. The purpose of this study was to assess the behavioral properties of clozapine, especially its effects on aggressive and motor behaviors. Individually housed male mice of the OF1 strain were exposed to anosmic “standard opponents” 30 minutes after the last drug administration. One category of animals received a sin…

MaleMale miceExperimental and Cognitive PsychologyAtypical neurolepticMotor ActivityPharmacologyMiceBehavioral NeuroscienceDopamine receptor D2medicineAnimalsClozapineClozapineDose-Response Relationship DrugDrug administrationMotor impairmentmedicine.diseaseAggressionLower affinityMotor SkillsSchizophreniaAnesthesiaArousalPsychologyPsychomotor Performancemedicine.drugPhysiology & Behavior
researchProduct

h-caldesmon immunoreactivity in atypical fibroxanthoma: implications for the differential diagnosis.

2017

MalePathologymedicine.medical_specialtySkin NeoplasmsSkin DiseasesH caldesmonPathology and Forensic MedicineDiagnosis Differential030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinemedicineXanthomatosisHumansAgedAged 80 and overHistiocytoma Benign Fibrousbusiness.industryAtypical fibroxanthomamedicine.diseaseImmunohistochemistry030220 oncology & carcinogenesisImmunohistochemistryCalmodulin-Binding ProteinsFemaleDifferential diagnosisbusinessPathology
researchProduct

Rufinamide in children and adults with Lennox-Gastaut syndrome: first Italian multicenter experience

2010

This is the first multicenter Italian experience with rufinamide as an adjunctive drug in children, adolescents and adults with Lennox-Gastaut syndrome. The patients were enrolled in a prospective, add-on, open-label treatment study from 11 Italian centers for children and adolescent epilepsy care. Forty-three patients (26 males, 17 females), aged between 4 and 34 years (mean 15.9 ± 7.3, median 15.0), were treated with rufinamide for a mean period of 12.3 months (range 3-21 months). Twenty patients were diagnosed as cryptogenic and 23 as symptomatic. Rufinamide was added to the baseline therapy at the starting dose of 10mg/kg body weight, evenly divided in two daily doses and then increased…

MalePediatricsLennox-Gastaut syndromeAtypical absence seizuresRufinamideLennox–Gastaut syndrome; Rufinamide; Orphan drug; Pediatrics; Epilepsy; Drop attacksInfantilePediatricsSpasmsEpilepsyRufinamideDrop attacks; Epilepsy; Lennox-Gastaut syndrome; Orphan drug; Pediatrics; Rufinamide; Adolescent; Adult; Anticonvulsants; Child; Child Preschool; Drug Therapy Combination; Female; Humans; Intellectual Disability; Italy; Lennox Gastaut Syndrome; Male; Spasms Infantile; Treatment Outcome; Triazoles; Valproic Acid; Young Adult; Neurology (clinical); NeurologyChildPediatricValproic AcidDrop attacksGeneral MedicineSettore MED/39 - Neuropsichiatria InfantileTreatment OutcomeItalyNeurologyAnesthesiaChild PreschoolCombinationVomitingAnticonvulsantsDrug Therapy CombinationFemalemedicine.symptomSpasms Infantilemedicine.drugAdultmedicine.medical_specialtyAdolescentClinical NeurologyIrritabilityYoung AdultDrug TherapyIntellectual DisabilitymedicineHumanspediatrics epilepsyPreschoolAdverse effectLennox–Gastaut syndrome; rufinamide; orphan drug; pediatrics epilepsy; drop attacks; refractory epilepsy.EpilepsyOrphan drugbusiness.industryLennox Gastaut SyndromeValproic Acidrefractory epilepsyTriazolesmedicine.diseaseNeurology (clinical)businessLennox–Gastaut syndromeLennox–Gastaut syndrome
researchProduct

Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.

2014

Atypical hemolytic-uremic syndrome (aHUS) is associated with genetic complement abnormalities/anti–complement factor H antibodies, which paved the way to treatment with eculizumab. We studied 44 aHUS patients and their relatives to (1) test new assays of complement activation, (2) verify whether such abnormality occurs also in unaffected mutation carriers, and (3) search for a tool for eculizumab titration. An abnormal circulating complement profile (low C3, high C5a, or SC5b-9) was found in 47% to 64% of patients, irrespective of disease phase. Acute aHUS serum, but not serum from remission, caused wider C3 and C5b-9 deposits than control serum on unstimulated human microvascular endotheli…

MaleTime FactorsClinical Trials and ObservationsComplement Membrane Attack Complexurologic and male genital diseasesBiochemistryGlomerulonephritisInside BLOOD Commentaryhemic and lymphatic diseasesMembranoproliferative glomerulonephritisMonoclonalHumanizedComplement ActivationAtypical Hemolytic Uremic SyndromeEndothelial CellHematologyRemission Inductionfood and beveragesHematologyComplement C3Eculizumabmedicine.anatomical_structureFactor HFemalecomplementaHUS eculizumabmedicine.drugMembranoproliferativeHumanmedicine.medical_specialtyEndotheliumMonitoringTime FactorGlomerulonephritis MembranoproliferativeImmunologyBiologyAntibodies Monoclonal HumanizedAntibodiesInternal medicineAtypical hemolytic uremic syndromemedicineHumansPhysiologicMonitoring PhysiologicAdenosine Diphosphate RiboseEndothelial CellsCell Biologymedicine.diseaseComplement systemImmunologyAdenosine Diphosphate Ribose; Antibodies Monoclonal Humanized; Atypical Hemolytic Uremic Syndrome; Complement Activation; Complement C3; Complement Membrane Attack Complex; Endothelial Cells; Female; Glomerulonephritis Membranoproliferative; Hemolytic-Uremic Syndrome; Humans; Male; Remission Induction; Time Factors; Monitoring Physiologic; Hematology; Biochemistry; Cell Biology; ImmunologyHemolytic-Uremic SyndromeComplement membrane attack complexBlood
researchProduct

Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice

2008

Efflux transporters, like P-glycoprotein (P-gp), may limit the access of drugs to the brain via the blood-brain barrier. The antipsychotic drug risperidone and its active metabolite 9-hydroxyrisperidone (paliperidone) are substrates of P-gp. Motor behavior of P-gp deficient mice (mdr1a/1b (-/-, -/-)) and wild type animals on a rotarod after acute doses of risperidone or haloperidol, a nonsubstrate of P-gp, were analysed aiming to show that P-gp substrate properties of an antipsychotic drug have functional consequences. Behavioral tests revealed dose-dependent effects of 0.3-3 mg/kg risperidone in wild type animals 0.5-12 h after i.p. injection of the drug. In knockout mice the 0.3 mg/kg dos…

Malemedicine.medical_specialtyATP Binding Cassette Transporter Subfamily BTime Factorsmedicine.drug_classAtypical antipsychoticMotor ActivityPharmacologyMiceBehavioral NeurosciencePharmacokineticsInternal medicinePaliperidone PalmitatemedicineHaloperidolAnimalsPaliperidoneATP Binding Cassette Transporter Subfamily B Member 1Chromatography High Pressure LiquidMice KnockoutPaliperidone PalmitateRisperidoneBehavior AnimalDose-Response Relationship DrugChemistryDopamine antagonistBrainIsoxazolesRisperidonePyrimidinesEndocrinologyPsychotropic drugArea Under CurveHaloperidolATP-Binding Cassette TransportersAntipsychotic Agentsmedicine.drugBehavioural Brain Research
researchProduct

Resolution of enuresis with aripiprazole in children with psychiatric disorders: two case reports

2021

Abstract Background Aripiprazole is a third-generation atypical antipsychotic drug that acts as a stabilizer of the dopaminergic and serotonergic system. As partial agonist of the dopamine (D2) and serotonin (5-HT1A) receptors, it appears to be effective in reducing mania in patients with bipolar disorder, tics in Tourette Syndrome, aggression in schizophrenia and autism spectrum disorder. Enuresis has been reported among its side effects. Only a few studies, with conflicting results, have investigated the relationship between aripiprazole and enuresis. Case presentation We report the disappearance of enuresis in a Caucasian girl with intellectual disability and oppositional defiant disorde…

Malemedicine.medical_specialtyAutism Spectrum Disordermedicine.drug_classmedicine.medical_treatmentAripiprazoleAtypical antipsychoticCase ReportAtypical antipsychoticTourette syndrome03 medical and health sciences0302 clinical medicineEnuresismental disordersmedicineHumansBipolar disorderChildPsychiatryAntipsychoticbusiness.industryRGeneral MedicineEnuresismedicine.disease030227 psychiatrySchizophreniaSchizophreniaMedicineFemaleAripiprazolemedicine.symptombusinessMania030217 neurology & neurosurgeryAntipsychotic AgentsNocturnal Enuresismedicine.drugJournal of Medical Case Reports
researchProduct

Typical Kawasaki disease with atypical pneumonia: a paediatric case report.

2020

Patients with complete Kawasaki disease (KD), in approximately 10–20% of cases, fail to defervesce with intravenous immunoglobulin (IVIG) infusion and acetylsalicylic acid (ASA) (1–5). Failure is u...

Malemedicine.medical_specialtyImmunologyMEDLINEMucocutaneous Lymph Node SyndromeMethylprednisolone03 medical and health sciences0302 clinical medicineRheumatologyhemic and lymphatic diseasesImmunology and AllergyMedicineHumans030212 general & internal medicineGlucocorticoids030203 arthritis & rheumatologybiologybusiness.industryImmunoglobulins IntravenousGeneral MedicinePneumoniamedicine.diseaseDermatologyKawasaki diseaseatypical pneumoniaIVIG treatmentpaediatric caseTreatment OutcomeAtypical pneumoniaChild Preschoolbiology.proteinKawasaki diseaseAntibodybusinessTomography X-Ray ComputedScandinavian journal of rheumatology
researchProduct